These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1067 related articles for article (PubMed ID: 34712233)

  • 1. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Wang X; Zhang B; Zhang Q; Zhou H; Sun Q; Zhou Y; Li T; Zhou D; Shen Z; Zhang J; Li P; Liang A; Zhou K; Han L; Hu Y; Yang Y; Cao J; Li Z; Xu K; Sang W
    Cancer; 2024 Aug; 130(15):2660-2669. PubMed ID: 38578977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
    Park JH; Nath K; Devlin SM; Sauter CS; Palomba ML; Shah G; Dahi P; Lin RJ; Scordo M; Perales MA; Shouval R; Tomas AA; Cathcart E; Mead E; Santomasso B; Holodny A; Brentjens RJ; Riviere I; Sadelain M
    Nat Med; 2023 Jul; 29(7):1710-1717. PubMed ID: 37400640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
    Chou CK; Turtle CJ
    Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
    [No Abstract]   [Full Text] [Related]  

  • 8. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
    Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.
    De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S
    Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
    Gardner RA; Ceppi F; Rivers J; Annesley C; Summers C; Taraseviciute A; Gust J; Leger KJ; Tarlock K; Cooper TM; Finney OC; Brakke H; Li DH; Park JR; Jensen MC
    Blood; 2019 Dec; 134(24):2149-2158. PubMed ID: 31697826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
    Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
    Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
    Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
    Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
    Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
    Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
    Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study.
    Caballero-Bellón M; Alonso-Saladrigues A; Bobillo-Perez S; Faura A; Arqués L; Rivera C; Català A; Dapena JL; Rives S; Jordan I
    Front Immunol; 2023; 14():1219289. PubMed ID: 37600775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
    Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.